Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01890265 · ClinicalTrials.gov registry record · Phase 2
Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 study, sponsored by Kyntra Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT01890265 is a Phase 2 study that has completed, run by Kyntra Bio. The registered enrollment target is 160 participants.
The verdict
NCT01890265, a Phase 2 study, has completed, sponsored by Kyntra Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of pamrevlumab in participants with IPF, and the efficacy of pamrevlumab in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these participants.
Interventions
- DRUG Placebo
- DRUG Pamrevlumab
- DRUG Sub-Study: Pirfenidone
- DRUG Sub-Study: Nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2013-07-30 |
| Est. Completion | 2017-11-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01890265
The ClinicalTrials.gov registry entry for NCT01890265 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01890265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01890265 about?
NCT01890265 is a clinical study titled "Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)". To evaluate the safety and tolerability of pamrevlumab in participants with IPF, and the efficacy of pamrevlumab in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these participants.
What is the current status of trial NCT01890265?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2013-07-30. Estimated completion is 2017-11-16.
What interventions are being tested in trial NCT01890265?
The interventions under investigation include: Placebo (DRUG), Pamrevlumab (DRUG), Sub-Study: Pirfenidone (DRUG), Sub-Study: Nintedanib (DRUG).
Who is sponsoring clinical trial NCT01890265?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.